[1] |
QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao.
Research Progress in Integration Sites for Cellular and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
|
[2] |
YU Yong, MA Shouliang, SHENG Yuqin.
Allergic Reactions and Treatment Involving Sodium Dimercaptopropane Sulfate Injection during Copper Chelation for Wilson’s Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 771-775.
|
[3] |
ZHU Huijuan, REN Jingtian.
Safety Risks of Human Rabies Immunoglobulin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
|
[4] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[5] |
CHEN Huan, LIANG Jun, ZHAO Wei, XIA Qingrong.
Clinical Features and Risk Factors of Liver Injury Induced by Atypical Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 410-414.
|
[6] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[7] |
WANG Shuan, HUANG Can, QI Lamei.
Establishment and Evaluation of Apatinib-Induced Hypertension Prediction Model Based on Real-World Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 429-435.
|
[8] |
LONG Minjuan, ZHAO Xu, GUO Longxin, CAI Yuhan, LIN Li, ZHU Shengkai, LIU Wenlong, SONG Haibo, XIAO Xiaohe.
Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 271-275.
|
[9] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[10] |
MIN Qiong, LI Peng, DAI Xiaoyan, FAN Chunling, YOU Haisheng.
One Case of Neurotoxicity Caused by Fluorouracil Injection in a Patient with Metastatic Colorectal Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 346-348.
|
[11] |
YANG Shengxi, XU Juntong, TU Wenlian.
Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.
|
[12] |
JIANG Haiyan, ZHOU Tianyu, FAN Xiaoyu, LI Wanfang, BAO Jie, JIN Hongtao.
Challenges to the current development of fixed-dose antitumor drug combinations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 961-966.
|
[13] |
GUO Shushu, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, MA Enlong, JIN Hongtao.
Rationality of compound drug components against hypertension
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 973-977.
|
[14] |
GUO Yuansheng, ZUO Tiantian, LIU Li'na, WEI Feng, DONG Zhe, LI Jing, JIN Hongyu, MA Shuangcheng.
Twenty-eight elements in Coicis Semen and risk assessment by stir-frying with bran by inductively coupled plasma-mass spectrometry
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1008-1013.
|
[15] |
ZHAO Peipei, WEN Baoshu.
Regulation of cellular and gene therapies at home and abroad
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
|